Posted by Michael Wonder on 30 Mar 2026
ICER to assess treatments for hypertension
30 March 2026 - Report will be subject of Midwest CEPAC meeting in October 2026; draft scoping document open to public comment until 17 April 2026.
The ICER announced today that it will assess the comparative clinical effectiveness and value of lorundrostat (Mineralys Therapeutics) and baxdrostat (AstraZeneca) for hypertension.
